CorMedix, Inc. (CRMD)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$5.23-7.60%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CRMD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -87.6% |
| Our one-year growth estimate | diamond | -34.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 52.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
CRMD — litigation filed
Dated 2026-11-02
Regulation FD Disclosure On November 2, 2026, the Company issued a press release providing a business update and announcing the Company’s cash position for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1, attached hereto. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated b…
Why it matters: The court has given early approval to a proposed settlement. A final ruling will show whether the case is resolved.
Watch forThe court grants final approval of the proposed settlement after the hearing.
Also watch forThe court rejects or delays final approval, or the case proceeds without a settlement.
Why it matters: The trial could support another DefenCath use. Management said it was aiming to finish enrollment in 2028.
Watch forThe company reports faster enrollment due to new sites or a protocol change. The trial remains on track to finish in 2028.
Also watch forThe company says enrollment is still slow, the protocol change is not approved, or the trial will end after 2028.
Why it matters: Approval would clear the way for a new use of REZZAYO. The FDA may also ask for more data or limit the label.
Watch forThe FDA approves the sNDA by its Q1 2027 target date. It aims to prevent invasive fungal disease in adults after allogeneic HSCT.
Also watch forThe FDA rejects the sNDA, asks for more data, extends review past Q1 2027, or grants a narrower label.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$156 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $602 loss on $10,000 · 6.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,892 loss on $10,000 · 58.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.